Lido Advisors
INBX

Lido Advisors’s Inhibrx, Inc. Common Stock INBX Stock Holding History

Lido Advisors’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-11,549
Closed -$207K – 1100
2022
Q3 		$207K Sell
11,549
-1,148
-9% -$20.7K ﹤0.01% 880
2022
Q2 		$144K Buy
+12,697
New +$187K ﹤0.01% 892

Other funds holding INBX

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Lido Advisors's INBX Position: Q4 2022 in Review

Lido Advisors sold out of Inhibrx, Inc. Common Stock (INBX) in Q4 2022, closing a stake of 11,549 shares — an estimated $207K sold.

Lido Advisors first reported a position in INBX in Q2 2022 and held it in 2 quarters. The position peaked at $207K in Q3 2022. 116 funds tracked by Wall St. Rank hold INBX as of Q4 2022.

  • Lido Advisors reported no remaining Inhibrx, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Lido Advisors sold 11,549 Inhibrx, Inc. Common Stock shares in Q4 2022, an estimated $207K.
  • Lido Advisors first reported a position in Inhibrx, Inc. Common Stock in Q2 2022 and held it in 2 quarters.
  • Lido Advisors's Inhibrx, Inc. Common Stock position peaked at $207K in Q3 2022.
  • 116 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q4 2022.

Based on Lido Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.